[go: up one dir, main page]

AR046096A1 - DERIVATIVES OF 4-PHENYLTIAZOL AND 4-PHENYLIMIDAZOL AND ITS USES AS A MEDICINAL PRODUCT - Google Patents

DERIVATIVES OF 4-PHENYLTIAZOL AND 4-PHENYLIMIDAZOL AND ITS USES AS A MEDICINAL PRODUCT

Info

Publication number
AR046096A1
AR046096A1 ARP040103665A AR046096A1 AR 046096 A1 AR046096 A1 AR 046096A1 AR P040103665 A ARP040103665 A AR P040103665A AR 046096 A1 AR046096 A1 AR 046096A1
Authority
AR
Argentina
Prior art keywords
thiazol
methyl
tert
amine
butyl
Prior art date
Application number
Other languages
Spanish (es)
Inventor
De Lassauniere Pierre-Etienne Chabrier
Harnett
Bigg
Liberatore
Pommier
Lannoy
Thurieau
Dong
Original Assignee
Sod Conseils Rech Applic
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US10/681,002 external-priority patent/US20040132788A1/en
Priority claimed from US10/915,001 external-priority patent/US7291641B2/en
Application filed by Sod Conseils Rech Applic filed Critical Sod Conseils Rech Applic
Publication of AR046096A1 publication Critical patent/AR046096A1/en

Links

Landscapes

  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Composiciones farmacéuticas que los comprende y usos. Reivindicación 1: Compuesto caracterizado porque se selecciona entre los siguientes: -2-[4-(4-aminofenil)-1H-imidazol-2-il]etilcarbamato de butilo; -N,2-dimetil-1-[4-(10H-fenotiazin-2-il)-1,3- tiazol-2-il]propan-1-amina; -N,2-dimetil-1-[4-(10H-fenoxazin-2-il)-1,3-tiazol-2-il]propan-1-amina; -N,3-dimetil-1-[4-(10H-fenoxazin-2-il)-1,3-tiazol-2-il]butan-1-amina; -N,3-dimetil-1-[4-(10H-fenotiazin-2-il)-1,3-tiazol-2-il]butan-1-amina; -2,6-di- tert-butil-4-{2-[3-metil-1-(metilamino)butil]-1,3-tiazol-4-il}fenol; -[4-(3,5-di-tert-butilfenil)-1,3-tiazol-2-il]metilamina; -2,6-di-tert-butil-4-{2-[(1S)-1-(metilamino)etil]-1,3-tiazol-4-il}fenol; -2,6-di-tert-butil-4-{2-[(1R)-1-(metilamino)etil]- 1,3-tiazol-4-il}fenol; -N-{[4-(3,5-di-tert-butilfenil)-1,3-tiazol-2-il]metil}-N-metilamina; -N-metil-N-{[4-(3,4,5-trimetoxifenil)-1,3-tiazol-2-il]metil}amina; -N-{[4-(3,5-di-tert-butil-4-hidroxifenil)-1,3-tiazol-2-il]metil}glicinato de etilo; -N-{[4- (3,5-di-tert-butil-4-hidroxifenil)-1,3-tiazol-2-il]metil}glicina; -2,6-di-tert-butil-4-{2-[(4-metoxipiperidin-1-il)metil]-1,3-tiazol-4-il}fenol; -N-metil-N-{(1S)-2-metil-1-[4-(10H-fenotiazin-2-il)-1,3-tiazol-2-il]propil}amina; -N,2-dimetil-1-[4-(10- metil-10H-fenotiazin-2-il)-1,3-tiazol-2-il]propan-1-amina; -N-metil-N-{(1S)-2-metil-1-[4-(10H-fenoxazin-2-il)-1,3-tiazol-2-il]propil}amina; -4-{2-[(1R)-1-aminoetil]-1,3-tiazol-4-il}-2,6-di-tert-butilfenol; -4-{2-[(1S)-1-aminoetil]-1,3-tiazol-4-il}- 2,6-di-tert-butilfenol; -4-[2-(1-aminociclopropil)-1,3-tiazol-4-il]-2,6-di-tert-butilfenol; -4-{2-[(metilamino)metil]-1,3-tiazol-4-il}benzene-1,2-diol; -N-metil-N-{(1R)-2-metil-1-[4-(10H-fenotiazin-2-il)-1,3-tiazol-2-il]propil}amina; -(1R)-2-metil-1- [4-(10H-fenotiazin-2-il)-1,3-tiazol-2-il]propan-1-amina; -N-metil-N-{(1R)-2-metil-1-[4-(10H-fenoxazin-2-il)-1,3-tiazol-2-il]propil}amina; -N,2-{[4-(3,5-di-tert-butil-4-hidroxifenil)-1,3-tiazol-2-il]metil}glicinamida; -N-{[4-(3,5-di-tert-butil-4- hidroxifenil)-1,3-tiazol-2-il]metil}-N-(2-etoxi-2-oxoetil)glicinato de etilo; -4-(3,5-di-tert-butil-4-metoxifenil)-2-(metoximetil)-1,3-tiazol; -4-[2-(1-aminociclopentil)-1,3-tiazol-4-il]-2,6-di-tert-butilfenol; o una sal de uno de ellos.Pharmaceutical compositions that comprise them and uses. Claim 1: Compound characterized in that it is selected from the following: -2- [4- (4-aminophenyl) -1H-imidazol-2-yl] ethylcarbamate; -N, 2-dimethyl-1- [4- (10H-phenothiazin-2-yl) -1,3-thiazol-2-yl] propan-1-amine; -N, 2-dimethyl-1- [4- (10H-phenoxazin-2-yl) -1,3-thiazol-2-yl] propan-1-amine; -N, 3-dimethyl-1- [4- (10H-phenoxazin-2-yl) -1,3-thiazol-2-yl] butan-1-amine; -N, 3-dimethyl-1- [4- (10H-phenothiazin-2-yl) -1,3-thiazol-2-yl] butan-1-amine; -2,6-di-tert-butyl-4- {2- [3-methyl-1- (methylamino) butyl] -1,3-thiazol-4-yl} phenol; - [4- (3,5-di-tert-butylphenyl) -1,3-thiazol-2-yl] methylamine; -2,6-di-tert-butyl-4- {2 - [(1 S) -1- (methylamino) ethyl] -1,3-thiazol-4-yl} phenol; -2,6-di-tert-butyl-4- {2 - [(1R) -1- (methylamino) ethyl] -1,3-thiazol-4-yl} phenol; -N - {[4- (3,5-di-tert-butylphenyl) -1,3-thiazol-2-yl] methyl} -N-methylamine; -N-methyl-N - {[4- (3,4,5-trimethoxyphenyl) -1,3-thiazol-2-yl] methyl} amine; -N - {[4- (3,5-di-tert-butyl-4-hydroxyphenyl) -1,3-thiazol-2-yl] methyl} ethyl glycinate; -N - {[4- (3,5-di-tert-butyl-4-hydroxyphenyl) -1,3-thiazol-2-yl] methyl} glycine; -2,6-di-tert-butyl-4- {2 - [(4-methoxypiperidin-1-yl) methyl] -1,3-thiazol-4-yl} phenol; -N-methyl-N - {(1S) -2-methyl-1- [4- (10H-phenothiazin-2-yl) -1,3-thiazol-2-yl] propyl} amine; -N, 2-dimethyl-1- [4- (10-methyl-10H-phenothiazin-2-yl) -1,3-thiazol-2-yl] propan-1-amine; -N-methyl-N - {(1S) -2-methyl-1- [4- (10H-phenoxazin-2-yl) -1,3-thiazol-2-yl] propyl} amine; -4- {2 - [(1R) -1-aminoethyl] -1,3-thiazol-4-yl} -2,6-di-tert-butylphenol; -4- {2 - [(1S) -1-aminoethyl] -1,3-thiazol-4-yl} -2,6-di-tert-butylphenol; -4- [2- (1-aminocyclopropyl) -1,3-thiazol-4-yl] -2,6-di-tert-butylphenol; -4- {2 - [(methylamino) methyl] -1,3-thiazol-4-yl} benzene-1,2-diol; -N-methyl-N - {(1R) -2-methyl-1- [4- (10H-phenothiazin-2-yl) -1,3-thiazol-2-yl] propyl} amine; - (1R) -2-methyl-1- [4- (10H-phenothiazin-2-yl) -1,3-thiazol-2-yl] propan-1-amine; -N-methyl-N - {(1R) -2-methyl-1- [4- (10H-phenoxazin-2-yl) -1,3-thiazol-2-yl] propyl} amine; -N, 2 - {[4- (3,5-di-tert-butyl-4-hydroxyphenyl) -1,3-thiazol-2-yl] methyl} glycinamide; -N - {[4- (3,5-di-tert-butyl-4- hydroxyphenyl) -1,3-thiazol-2-yl] methyl} -N- (2-ethoxy-2-oxoethyl) ethyl glycinate ; -4- (3,5-di-tert-butyl-4-methoxyphenyl) -2- (methoxymethyl) -1,3-thiazole; -4- [2- (1-aminocyclopentyl) -1,3-thiazol-4-yl] -2,6-di-tert-butylphenol; or a salt from one of them.

ARP040103665 2003-10-08 2004-10-08 DERIVATIVES OF 4-PHENYLTIAZOL AND 4-PHENYLIMIDAZOL AND ITS USES AS A MEDICINAL PRODUCT AR046096A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10/681,002 US20040132788A1 (en) 1999-10-11 2003-10-08 Derivatives of heterocycles with 5 members, their preparation and their use as medicaments
US10/915,001 US7291641B2 (en) 1999-10-11 2004-08-10 Derivatives of heterocycles with 5 members, their preparation and their use as medicaments

Publications (1)

Publication Number Publication Date
AR046096A1 true AR046096A1 (en) 2005-11-23

Family

ID=43016529

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP040103665 AR046096A1 (en) 2003-10-08 2004-10-08 DERIVATIVES OF 4-PHENYLTIAZOL AND 4-PHENYLIMIDAZOL AND ITS USES AS A MEDICINAL PRODUCT

Country Status (1)

Country Link
AR (1) AR046096A1 (en)

Similar Documents

Publication Publication Date Title
BRPI0815142B8 (en) crystalline form of the dihydrochloride salt ((1s)-1-(((2s)-2-(5-(4'-(2-((2s)-1-((2s))-2-((methoxycarbonyl)amino methyl)-3-methylbutanoyl)-2-pyrrolidinyl)-1h-imidazol-5-yl)-4-biphenylyl)-1h-imidazol-2-yl)-1-pyrrolidinyl)carbonyl)-2-methylpropyl)carbamate.
AR044825A1 (en) DERIVATIVES OF 5,6-DIARIL-PIRAZINAS-2-CARBOXAMIDE AND -2-SULPHONAMIDS -3-REPLACED AS MODULATORS OF CB1
CL2018003290A1 (en) Heterocyclic amides useful as protein modulators (divisional application cl 2850-2018).
NZ594981A (en) Hepatitis c virus inhibitors
HRP20120440T1 (en) HEPATITIS VIRUS INHIBITORS C
AR055734A1 (en) A SOLID FORMULATION OF PHARMACEUTICAL DOSAGE
CL2008002131A1 (en) Heterocycle amide compounds derived from heterocycle substituted and heterobicyclic pyrimidines, protein kinase inhibitors; pharmaceutical composition; and use of the compounds in the treatment of proliferative, neurological or neurodegenerative, cardiovascular, viral or fungal diseases.
RU2010128512A (en) HETEROCYCLIC MEK INHIBITORS AND WAYS OF THEIR APPLICATION
PE20170148A1 (en) 1,3,4-TIADIAZOLE COMPOUNDS AND USE OF THEM FOR THE TREATMENT OF CANCER
CL2011000933A1 (en) The compound 2 - [(5-chloro-2 - {[3-methyl-1- (1-methyl ethyl) -1h-pyrazol-5-yl] amino} -4-pyridinyl) amino] -n- (methyloxy) benzamide and its salts, focal adhesion kinase inhibitor (fak); pharmaceutical composition that includes it; and its use for the treatment of cancer.
CL2008000750A1 (en) METHOD FOR THE ADMINISTRATION OF A WEEKLY DOSE OF 2- [6- (3-AMINO-PIPERIDIN-1-IL) 3-METHYL-2,4 DIOXO-3,4 DIHYDRO-2H-PIRIMIDIN-1-IL METIL] -4 FLUORO-BENZONITRILE; PHARMACEUTICAL COMPOSITION OF AN INDIVIDUAL DOSAGE FORM OF SUCH COMPOUND; AND HIS
EA201200096A1 (en) PHARMACEUTICAL COMPOSITION OF THE HYPATITIS VIRUS PROTEASE INHIBITOR INHIBITOR
GT200600496A (en) SALTS, PROFARMS AND FORMULATIONS OF 1- [5- (4-AMINO-7-ISOPROPIL-7H-PIRROLO [2,3-D] PIIRIMIDIN-5-CARBONIL) -2-METOXI-FEIL] -3- (2,4 -DICLORO-PHENIL) -UREA.
EA201000300A1 (en) METHOD FOR SYNTHESIS OF COMPOUNDS SUITABLE FOR THE TREATMENT OF HEPATITIS C
CL2008002142A1 (en) Compounds derived from 2-amino-6 - ({[2- (4-chlorophenyl) -1,3-thiazol-4-yl] methyl} thio) -4- [4- (2-hydroxyethoxy) phenyl] pyridin-3 , 5-dicarbonitrile; preparation procedure; Pharmaceutical composition and use in cardiovascular diseases.
CA2536182A1 (en) Macrocyclic peptides active against the hepatitis c virus
CO6321225A2 (en) SOLID CARRIER PARTICLES TO IMPROVE THE PROCESSABILITY OF A PHARMACEUTICAL AGENT
SI3184523T1 (en) N-((4,6-dimethyl-2-oxo-l,2-dihydropyridin-3-yl)methyl)-5-(ethyl (tetrahydro-2h-pyran-4-yl)amino)-4-methyl-4'-(morpholinomethyl)-(l,1'-biphenyl)-3-carboxamide hydrobromide for use in the treatment of a cell proliferative disorder of the hematologic system
CL2007002128A1 (en) DERIVATIVES OF N'-CIANO-N-HALOGENOALQUIL-IMIDAMIDA; PROCEDURE FOR THE PREPARATION OF SUCH COMPOUND; PHARMACEUTICAL COMPOSITIONS THAT CONTAIN IT; AND USE OF THE COMPOUND TO COMBAT ANIMAL PARASITES.
ECSP099780A (en) NEW MACROCICLIC INHIBITORS OF HEPATITIS C VIRUS REPLICATION
PA8799901A1 (en) 1,3,5-TRISUSTITUTED TRIAZOL DERIVATIVE
AR069513A1 (en) DERIVATIVES OF AMIDAS OF THE ACID 6,7-DIHIDRO -5H-IMIDAZO1,2-ALFA] IMIDAZOL-3-CARBOXILICO, AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
ECSP099767A (en) DERIVATIVES OF N '- (PHENYL) -N- (MORFOLIN-4-IL-PIRIDIN-2-IL) -PIRIMIDINA-2, 4-DIAMINE AS EPHB4 KINASE INHIBITORS FOR THE TREATMENT OF PROLIFERATIVE AFFECTIONS
MX2022001743A (en) SOLID STATE FORMS OF (S)-2-(((S)-6,8-DIFLUOR-1,2,3,4-TETRAHI DRONAFTALEN-2-IL)AMINO)-N-(1-(2-METHYL) -1-(NEOPENTYLAMINO)PROPAN-2- IL)-1H-IMIDAZOLE-4-IL)PENTANAMIDE AND USES THEREOF.
CL2021001629A1 (en) Halo-allylamine compounds and use thereof

Legal Events

Date Code Title Description
FA Abandonment or withdrawal